Skip to main content
. 2017 Feb 4;8(9):14294–14305. doi: 10.18632/oncotarget.15104

Figure 4. Pravastatin increases the levels of MMP2 protein and activity in murine VSMCs, which depends on AMPK and AP-2α.

Figure 4

A. Mouse VSMCs were treated with pravastatin for 24 hours as indicated concentrations. B. Cultured VSMCs were pretreated with tempol (10 μM, 30 minutes) followed by co-incubation of pravastatin (50 μM) for 24 hours. C. VSMCs were pretreated with compound C. (20 μM, 30 minutes) followed by co-incubation of pravastatin (50 μM) for 24 hours. D. and E. Cultured VSMCs transfected with D. AMPKα2 siRNA or E. AP-2α siRNA for 48 hours were incubated with pravastatin (50 μM) for 24 hours. Total cell lysates in A.-E. were subjected to perform western blot analysis of the level of MMP2 proteins. The activity of MMP2 in culture medium in C.-E. was assayed by zymography. The N is 3 in each group. One-way ANOVA followed by Tukey post-hoc tests was used for multiple comparisons. In A., *P < 0.05 vs. point 0. In B.-E., *P < 0.05 vs. Vehicle or control siRNA alone. NS indicates no significance.